Navigation Links
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Date:6/1/2009

First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL

ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ --

Intent to treat Analysis results per FDA agreed upon Statistical Analysis Plan

  • Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021
  • Significant Increase in Overall Response Rate 37.1% vs. 14.3%; p=0.003
  • Significant increase in percent of all patients whose response lasted greater than or equal to four months 25.7% vs. 8.6%; p=0.012
  • Significant Increase in Progression Free Survival 4.7 months vs. 2.6 months; p=0.007
  • Positive trend in Overall Survival even though data not fully mature with median 8.1 month vs. 6.9 month; p=0.544

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that at the 2009 American Society for Clinical Oncology ("ASCO") Annual Meeting for the first time since the top-line data were released, complete pivotal phase III results of CTI's EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") were presented by Principal Investigator, Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial who presented the study at ASCO.

"Anthracycline-related drugs can be effective salvage agents in aggressive NHL, but our use of them is limited by the significant increase in risk of cardiac failure associated with high cumulative doses of these drugs," said Dr. Pettengell. "These results represent a breakthrough in that pixantrone could extend our ability to use a highly active anthracycline-like drug in such patients and deserves to be examined in anthracycline naive patien
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
2. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
3. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
7. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
8. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
9. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
10. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
11. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 ... that Roger Jeffs , Ph.D., President and Co-Chief Executive ... on the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on ... can be accessed via a live webcast on the United ...
(Date:4/30/2015)... 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... that it has commenced an underwritten public offering of ... the underwriters a 30-day option to purchase up to ... stock offered in the public offering. The offering is ... assurance as to whether or when the offering may ...
(Date:4/30/2015)... , April 30, 2015  The Paul G. ... Distinguished Investigator (ADI) grants to six groups of researchers ... most challenging roadblocks in neuroscience: growing mature human brain ... a total of $7.5 million over three years.  ... and their research is especially significant because the field ...
(Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Fleur’s ... multi-action product combining the benefits of makeup, skin ... This subtly tinted cream is designed with specific ... for an even complexion and a healthy glow. ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3
... talks are among those that will be presented by ... Laboratory at the American Physical Society meeting, March 10-14, ... Please note that the content of each talk is ... below. All of the research described below was funded ...
... Medco Health,Solutions, Inc. (NYSE: MHS ) announced ... principal amount of 6-1/8 percent senior notes due March,15, ... percent,senior notes due March 15, 2018 in an underwritten ... Securities LLC and Barclays,Capital Inc. are acting as representatives ...
... 14 at 8:00 a.m. PDT ... ... (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing products targeting the ... December 31, 2007., "Our achievements in 2007 have advanced our partnered ...
Cached Biology Technology:News from the March 2008 American Physical Society Meeting 2News from the March 2008 American Physical Society Meeting 3News from the March 2008 American Physical Society Meeting 4News from the March 2008 American Physical Society Meeting 5Medco Issues $1.5 Billion of Senior Notes 2Medco Issues $1.5 Billion of Senior Notes 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... are improving the taste, appearance and nutritional content of ... grow to $6 billion by 2017, according to a ... (IFT) Annual Meeting & Food Expo in Chicago. ... an immune disorder triggered by the ingestion of gluten ...
... tissue sustains irreparable damage in the wake of a ... and the cardiac muscle contains few stem cells, the ... fibrotic and cannot contract properly. In their search ... been exploring cardiac "patches" that could be transplanted into ...
... to cancer and other diseases, genetic testing, infectious proteins ... topics internationally renowned speakers will tackle at The EMBO ... from 21-24 September 2013. Sir Michael Stratton, Director ... Executive Officer of deCODE Genetics, and Thijn Brummelkamp, Group ...
Cached Biology News:New technologies and ingredients provide better options for gluten-free eating 2A heart of gold 2Anne Glover and Sir Michael Stratton to meet the press at The EMBO Meeting 2013 in Amsterdam 2
Mouse Anti-Gemin2...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
... for cryogenic vials. Racks ... stainless steel boxes for 2ml, ... Vapor phase or Liquid ... risers to be ordered separately ...
... J. Karn (1995) This ... information and methods for the study of ... cycle; reverse transcriptase, ribonuclease H, integrase and ... RNA binding assays; Tat and Rev assays; ...
Biology Products: